All In Biotech

Drug Trial Radar · NCT00848549

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Last checked: Nov 20, 2026Latest source record: Dec 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 295 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

295

Actual

Start

Oct 2008

Primary completion

Jun 2011

Study completion Nov 2011

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Feb 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.

Conditions

  • Epilepsy

Interventions

  • ZonisamideDrug

    Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.

  • CarbamazepineDrug

    Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Remaining in the Study at Each VisitTime frame: At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months

Locations

133 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Queensland, Australia

  • Site not named

    Camperdown, New South Wales, Australia

  • Site not named

    Bedford Park, South Australia, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Fitzroy, Victoria, Australia

  • Site not named

    Heidelberg West, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Perth, Western Australia, Australia

  • Site not named

    Aalborg, Denmark

  • Site not named

    Béthune, France

  • Site not named

    Dijon, France

  • Site not named

    Paris, France

  • Site not named

    Saint-Etienne, France

  • Site not named

    Berlin, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Munich, Germany

  • Site not named

    Schwerin, Germany

  • Site not named

    Westerstede, Germany

  • Site not named

    Athens, Greece

  • Site not named

    Athens, Greece

  • Site not named

    Athens, Greece

  • Site not named

    Pátrai, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Thessaloniki, Greece

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Budapest, Hungary

  • Site not named

    Debrecen, Hungary

  • Site not named

    Gyula, Hungary

  • Site not named

    Hódmezővásárhely, Hungary

  • Site not named

    Nyregyhaza, Hungary

  • Site not named

    Zalaegerszeg-Poozva, Hungary

  • Site not named

    Bangalore, India

  • Site not named

    Bangalore, India

  • Site not named

    Hyderabad, India

  • Site not named

    Koturpuram, Chennai, India

  • Site not named

    Madurai, Tamil Nadu, India

  • Site not named

    Mumbai, India

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.